ASX healthcare shares didn’t, as a whole, have the best of years in 2020.

In fact, Randal Jenneke – head of Australian equities at the US investment firm T Rowe Price – says healthcare just suffered through its worst year in a decade.

But he believes that’s all turning around.

And in the hunt for what Jenneke labels “quality growth” stocks, ASX healthcare shares are under the microscope.

Leading ASX healthcare share “really attractive”

According to Jenneke (quoted by the Australian Financial Review):

That’s where we see good opportunity. ResMed is an example of a stock that we think is really attractive. Valuations are back to the most attractive level in five years. As the US economy reopens, the sleep business can get back to normal and there’s a new product cycle coming.

If you’re not familiar with the company, ResMed CDI (ASX: RMD) is a leading S&P/ASX 200 Index (ASX: XJO) healthcare share.

Its primary business is developing respiratory medical devices, with a focus on the treatment of sleep apnoea. During the height of the COVID epidemic, ResMed also turned its attention to the production of respirators.

Based in the US state of California, the ASX healthcare share operates in more than 140 countries. It has manufacturing facilities in Australia, Singapore, France, and the US.

ResMed first listed on the ASX in November 1999, trading for less than $1 per share. Today it has a market cap of $41 billion.

ResMed share price snapshot

Over the past 12 months the ResMed share price has gained 19%, trailing the 22% gains posted by the ASX 200 over that same time.

Year-to-date the ASX health care share has gained 3.2% and is currently trading at $28.47 per share.

ResMed also pays a smallish dividend yield of 0.5%, unfranked.

The post Blue chip ASX healthcare share “really attractive”: top analyst appeared first on The Motley Fool Australia.

More reading

• What I regret about my Afterpay (ASX:APT) shares: analyst
• Is the ResMed (ASX:RMD) share price good value?
• 5 things to watch on the ASX 200 on Wednesday
• 3 highly rated ASX growth shares analysts love
• 2 blue chip ASX shares rated as buys

Bernd Struben does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3zgVtiD

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

Shares of coronavirus vaccine maker Novavax (NASDAQ: NVAX) tanked by 37.7% in May, according to data provided by S&P Global Market Intelligence. The collapse was a result of the company’s repeated delays with the manufacturing of its coronavirus vaccine as well as its announcement that it won’t file for the candidate’s regulatory approval before the third quarter.

So what

The combination of delays with regulatory filings and manufacturing delays means that Novavax won’t be able to deliver its contractually obligated doses to the European Union before 2022. In short, certain raw materials needed for the vaccine are in scant supply. Furthermore, the company will be even further behind other vaccine makers like Pfizer and Moderna, which are already on the market and in wide distribution.

In the long run, however, these issues probably won’t harm the company’s revenue making potential. Even amid the delays, Novavax is still signing new sales agreements with groups like the Gavi Vaccine Alliance, which agreed to buy 350 million doses of its vaccine on May 6. Likewise, Novavax still has commitments to make more than 1.1 billion doses in conjunction with its manufacturing collaborators. So, while May’s losses might be frustrating, they probably don’t reflect much genuine destruction of shareholder value. It’s likely that the stock will rebound once sales revenue starts to be reflected in earnings reports.

Now what

While investors are unlikely to have much patience for further delays, Novavax is still proceeding with its plans to commercialize its coronavirus vaccine globally, and it will almost certainly continue to succeed in doing so. Notably, in early May it also reported that its candidate is effective against at least one viral variant, which should keep it competitive with the currently marketed vaccines. But shareholders will need to wait a bit longer before the full impact of the revenue is reflected in the company’s quarterly earnings reports.

Beyond that, the company is also pursuing its combination vaccine project, which could inoculate people against both influenza and the coronavirus in a single jab. On May 10, it published preliminary evidence from preclinical studies that suggests the combination vaccine could be effective.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Why shares of Novavax crashed 37.7% in May appeared first on The Motley Fool Australia.

More reading

• Why the Premier Investments (ASX:PMV) share price just hit a record high
• The Imugene (ASX:IMU) share price has fallen 14% in the last 5 days
• Why the Fatfish (ASX:FFG) share price is rocketing 38% higher today
• Here’s why the Syrah (ASX:SYR) share price is pushing higher today
• Moderna files for FDA approval of its COVID vaccine in teens

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/3cwDElG

The Premier Investments Limited (ASX: PMV) share price popped into record territory this morning after the company provided a 2H21 and FY21 trading update.

In early morning trade, the company’s share price jumped by 5.2% to hit a new, all-time high of $28.75. However, at the time of writing, Premier shares have retreated back to $27.37, 0.15% higher for the day so far.

Let’s take a look at the latest news from Premier.

Trading update

The Premier share price received a boost this morning after the company announced its strong trading momentum has continued into the second half of FY21.

Premier advised that total global sales for the first 18 weeks of 2H21 ended 5 June 2021 had surged 70% against the comparable period in 2H20 and was up 15.8% against the comparable 18 weeks of 2H19.

The group’s upbeat trading result was driven by a particularly strong performance during the “all-important” Easter School Holiday period, alongside a record Mother’s Day and May result.

Looking ahead, the company expects FY21 earnings before interest and tax (EBIT) to be in the range of $340 million and $360 million. This represents an increase of between 82% and 92% against FY20 EBIT and between 103% and 115% against FY19 EBIT.

Premier points to strong customer demand for its winter product range across all brands, continued strength in online sales and margin expansion as key drivers of its anticipated record FY21 EBIT.

It is worth taking into account that the forecasted record FY21 result comes with the assumption that retail trading conditions remain strong, with no further COVID-19-related store closures or mobility restrictions that could influence consumer shopping decisions.

Management commentary

Premier Investments executive director and CEO Mr Mark McInnes commented on the strong results:

Today’s FY21 EBIT upgraded range will represent another record result for Premier’s shareholders. The strategic decision taken last year by the Chairman and I to build our supply chain and significantly invest in wanted inventory for Easter, April school holidays, Mother’s Day and the winter season has ensured we are in stock, delivering strong sales and gross margin growth across all our brands.

The Group has successfully enabled customers to shop seamlessly either online or in-store during the COVID-19 health crisis. This has been achieved through the long term strategic investments made in our online capability combined with our ability to reach mutual agreements with landlords to appropriately rebase rents.

Premier Investments share price snapshot

Premier Investments has released several upbeat trading announcements this year, which were followed by a pop in its share price.

On 13 January, the company released a positive 1H21 trading update that saw the Premier share price shoot as much as ~18% higher to $26.70.

Premier Investments shares jumped again on 24 March, following the release of the company’s half-year results. The shares opened 8% higher on the day to $25.85 before closing 4.65% higher at $24.94.

Similarly, investors have responded positively to today’s trading update, sending Premier shares into record territory.

The post Why the Premier Investments (ASX:PMV) share price just hit a record high appeared first on The Motley Fool Australia.

More reading

• 2 ASX 200 shares that could be reliable picks for dividends
• Retail sales rose 1.1% in April, but some ASX retail shares are selling off in May
• 2 ASX 200 shares to buy for growth

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Premier Investments Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3vcMRGC

Shares in Imugene Limited (ASX: IMU) continue to be among the most traded shares on the market. Unfortunately for investors, the Immugene share price has been on a heavy losing streak this week, falling 14% in the last 5 days.

Imugene is a clinical stage immuno-oncology company currently developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.

The company is conducting a number of trials including HER-Vaxx, an immunotherapy to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The Imugene share price has been volatile recently, rising from 12 cents in April to a record high of 50 cents at the end of May, more than tripling its value.

June has brought a change in fortune, however, with shares sliding back to their current price of 32.5 cents apiece. With no negative announcements from the company, let’s take a look at what’s been happening recently.

Recent announcements

Since April, the company has released several announcements that have sent the Imugene share price surging higher.

One significant release came on 21 April when Imugene announced that the second clinical endpoint for its HER-Vaxx clinical studies had been met.

On 18 May, Imugene declared it had entered into an agreement with City of Hope, an independent cancer research and treatment centre, to license the patent for its CD19 therapy.

It was a world first, with the technology under the license being an extension of chimeric antigen receptor (CAR) T cell cancer therapy, which has the potential to treat solid cancers. Imugene plans to begin its first clinical trial of CD19 in 2022.

Following that announcement, banking firm FROTH Capital raised the Immugene share price target to 42 cents. This was based on a number of factors, including the projected future revenue of Imugene CHECKvacc, HER-Vaxx, and PD1-Vaxx trials.

With the biotech’s surging share price a likely reflection of its significant announcements in the world of immunology, the latest price drop is a bit of a mystery. It’s possible there could be some profit-selling at play.

The good news today is the Imugene share price is lifting again, up 3.8% trading at 32.5 cents at the time of writing.

The post The Imugene (ASX:IMU) share price has fallen 14% in the last 5 days appeared first on The Motley Fool Australia.

More reading

• These 3 ASX 200 shares are the most actively traded today
• These 3 ASX 200 shares were among the biggest movers today
• Why A2 Milk, ASX Ltd, Galaxy, & Imugene shares are dropping today
• Imugene and Zip were among the most traded ASX shares last week
• Why the Imugene (ASX:IMU) share price is up 13% to a record high

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3gd91nS

The Fatfish Group Ltd (ASX: FFG) share price has returned from its week-long suspension with a bang.

In early trade, the technology venture company’s shares were up as much as 38% to 10.5 cents.

The Fatfish share price has since eased back but remains up 18.5% to 9 cents at the time of writing.

Why is the Fatfish share price zooming higher?

The Fatfish share price is zooming higher today after the company announced an agreement to acquire BNPL Next for a consideration of A$4.14 million.

The release explains that BNPL Next is a holding company that aims to provide various corporate and consumer financial services in the South East Asia market.

The company also owns a 60% interest in Circopay, which is an Earned Wage Access (EWA) solutions provider allowing employees early access to earned wages. It has raised just over A$1million in funding and secured credit lines of A$5 million to facilitate its EWA services.

Management notes that the Circopay business is in an early growth phase and therefore it is not able to quantify the revenue income for Fatfish as a proposed 60% shareholder. If and when the revenue impact of the Circopay business can be responsibly determined, Fatfish will make further disclosure to the market at that time.

Why acquire BNPL Next?

According to the release, management believes the acquisition of BNPL Next fits into its strategy to invest in and build on emerging global technology trends in digital financing needs. This is especially the case given its existing plan to roll out buy now pay later (BNPL) services across Southeast Asia.

In addition to this, it believes the EWA market is an attractive place to be. This is due to its “win-win nature for both employees and employers.”

Another positive it sees from the deal is the first-mover advantage it gives the company. It notes that as one of the pioneer EWA service providers in Southeast Asia (where a large proportion of the working population have comparatively lower income as well as limited access to financial services), Circopay is poised to capitalise on its first-mover advantage within the region.

Despite today’s strong gain, the Fatfish is down a whopping 79% from its 52-week high.

The post Why the Fatfish (ASX:FFG) share price is rocketing 38% higher today appeared first on The Motley Fool Australia.

More reading

• Fatfish (ASX:FFG) shares in trading halt pending BNPL acquisition

James Mickleboro does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3g9RzjU

The Syrah Resources Ltd (ASX: SYR) share price is pushing higher on Friday morning.

At the time of writing, the graphite producer’s shares are up 2% to $1.08.

Why is the Syrah share price pushing higher?

Investors have been bidding the Syrah share price higher today after it announced its decision to issue a $28 million (US$22 million) convertible note tranche to AustralianSuper.

This follows the signing of an agreement in December with the super fund, which gave Syrah the option issue convertible notes totalling A$56 million (US$43 million) in two tranches.

While the first $28 million (US$22 million) tranche was not issued earlier this year due to its strong balance sheet position, the second tranche has been issued to support the orderly ramp-up of production at Balama under various market scenarios.

The funds will also be used to maintain project momentum for the proposed expansion of production capacity at its Active Anode Material Facility in Vidalia, USA.

Market conditions improve

The release explains that electric vehicle, anode material and natural graphite market conditions are constructive. This is supporting the ramp-up of production at Balama towards an initial target of 15kt per month.

Though, it stressed that it is continuing to be disciplined in its ramp-up at Balama by considering market demand and leading indicators.

Over in the United States, the Initial Detailed Design for the expansion of production capacity at Vidalia has improved the definition of costs in the Bankable Feasibility Study (BFS). Pleasingly, the estimated capital costs for the construction of a 10ktpa AAM facility at Vidalia remain consistent with the BFS, with the full proposed contingency being maintained.

Syrah’s cash position as at 30 June 2021, which will include proceeds from the note issue, is expected to be US$81 million.

The post Here’s why the Syrah (ASX:SYR) share price is pushing higher today appeared first on The Motley Fool Australia.

More reading

• Short sellers who sledge ASX companies put on notice
• Syrah (ASX:SYR) share price edges higher on positive update

James Mickleboro does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3pFcgYi

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

On Thursday, Moderna (NASDAQ: MRNA) announced it has filed for Emergency Use Authorization for its COVID-19 vaccine in adolescents from 12 to 18. If the agency gives Moderna a green light, parents will have another vaccine option beyond Pfizer (NYSE: PFE) and BioNTech‘s (NASDAQ: BNTX) vaccine, which was approved for ages 12 to 18 in May.

The coronavirus can be spread easily, and so far, over 174 million cases and 3.7 million deaths have been attributed to the disease worldwide.

Drugmakers including Moderna have developed vaccines to help prevent severe disease, and over the past few months, governments have made significant progress in vaccinating adult populations. For example, over 304 million COVID vaccine doses have been administered in the U.S., with 52% of Americans having received at least one dose.

The vaccination rate in children is lower, with only 23% of Americans under 18 having received at least one dose, but that rate should improve as more vaccines secure FDA approval. The agency expanded emergency use of Pfizer’s COVID vaccine to include children over 12 last month, and a meeting of its advisory committee to discuss vaccinating adolescents is happening this week. 

Investigators observed no COVID cases in Moderna’s study of patients ages 12 to 18, and safety outcomes were similar to those for adults, suggesting the vaccine could win emergency approval soon.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Moderna files for FDA approval of its COVID vaccine in teens appeared first on The Motley Fool Australia.

More reading

• Here’s how Moderna plans to beat the biggest threat to its vaccine
• Moderna’s teen COVID-19 vaccine trial hits high marks
• CSL (ASX:CSL) share price backtracks despite renewed optimism
• Australia eyes Moderna (NASDAQ:MRNA) COVID-19 vaccine delivery
• What the Federal Budget could mean for CSL (ASX:CSL) shares

Todd Campbell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/2TdKDcB

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Investing in digital currencies, especially in the extremely hot coins, requires a little bit of industry knowledge and a whole lot of DYOR-ing. Luckily, once you’ve mastered both, you can be on your way to making more thoughtful — and potentially lucrative — decisions in cryptocurrency investments.

With the current crypto market cap looking at an eye-popping $1.5 trillion, and over 10,000 coins to choose from, more and more investors are adding digital currencies to their portfolios. As a result, the days of holding only the Big Two, Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) are, quite frankly, passé.

In the hope that they’ll strike gold by pulling the trigger on the newest trending altcoin (any coin that is not Bitcoin), many investors rush in, chasing the pump. While I appreciate that new crypto investors are eager and sometimes overly confident, I do believe in being conservative.

That is until you know what you are doing and how you limit your losses. With this in mind, let’s take a deep dive into the trusted hacks that measure any altcoin’s stability. 

The 7 crypto golden rules

Go to the DEX (decentralized exchange) of your choice, and search for coins that have been on your radar. Keep all options open. Otherwise, you might miss out on some real gems. Don’t follow the market. Follow the numbers.

Then, click on your selections, follow these steps, and compare each coin side by side as if your life (rather, your wallet) depends on it.

And remember, don’t chase the pump!

1. Research: Be wary of the news and coins that are being shilled on Reddit as well as social media. When investigating a coin, see what kind of project it is supporting and if there is good value behind it. In other words-is it just another “memecoin” or is it attached to something innovative? Even better-join the coin’s Telegram channel and see what people are generally saying about the coin itself.
2. Volume: Click on the Volume tab as your primary filter. The highest volume coins are moving the fastest at low opportunity costs. This reduces the chances of getting trapped in a pump-and-dump.
3. Percentage change: Check out the moving average indicator line. If you see a sudden, sharp drop from a coin’s all-time high, you don’t want to invest in it, because this coin has already broken its upswing trend and you risk losing money.
4. If it’s a solid uptrend: It’s ok to buy high and sell higher, especially in a bull market.
5. Market cap: Although not a deal breaker, it’s nice to see that a coin has a high market cap. The higher the market cap, the more people have invested in this particular coin. Therefore, comparing all your coins here is always a good idea.
6. Circulating supply: If this is an infinite number, you’re in trouble. This coin will go nowhere in value and fast. On the other hand, a healthy coin should have an excellent circulating supply in the multi-millions and beyond. 
7. TVL (Total Value Locked): Simply put, TVL shows that there is enough money locked into a coin to initiate its actual launch. This is an actual funding pool that lenders deposit money into. It shows exactly how much risk has gone into a coin. In fact, I would worry if a coin’s TVL was under $1 million (for a new coin) and under $300 million for an established coin. But again-the higher the better.

And that’s pretty much it!

Once you get the hang of things, you’ll be able to invest like a crypto expert. Always remember to investigate and compare all options. Did coin #1 not meet any of the 7 rules? Run for the hills. Ask yourself if you really want to get in. Did coin #3 check all the boxes? Great! Just remember to always research the heck out of each option, make sure it serves a legitimate purpose, and avoid falling for coins that promise to go “to the moon!” 

We all know what happened with that last one.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post 7 golden rules for crushing your crypto investments appeared first on The Motley Fool Australia.

More reading

• In a world first, El Salvador makes Bitcoin legal tender
• How Aussies raked in $260 million in Bitcoin profits in 2020
• Bitcoin stocks tumble after authorities recover ransom paid by Colonial Pipeline
• Bitcoin slammed as “least favourite asset for investment”
• Could this be the first country to adopt Bitcoin as legal tender?

Isabelle Korman owns Bitcoin and Ethereum. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Bitcoin. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/3wk53iY

The Domino’s Pizza Enterprises Ltd (ASX: DMP) share price is on course to end the week on a positive note.

In early trade, the pizza chain operator’s shares are up 2% to $116.60.

Why is the Domino’s share price pushing higher?

The catalyst for the rise in the Domino’s share price higher today has been the release of an acquisition announcement.

According to the release, the company has entered into a binding agreement with Formosa International Hotels Corporation to acquire the corporate stores and franchise rights held by Domino’s Taiwan for A$79 million on a cash and debt free basis.

The release notes that Domino’s Taiwan has the second largest pizza chain in the Taiwanese market, with a sophisticated network of 138 franchised stores and 19 corporate stores.

Furthermore, the stores are located across all major cities with substantial opportunity for further growth. In fact, management intends to significantly expand the business, with a long term aspiration of 400+ stores and delivering growth in its average weekly unit sales.

To help it achieve these goals, Domino’s plans to work with experienced local pizza experts who built a solid foundation in the market. It will also add its proven technology (including online platform OneDigital) and operational innovations.

In addition to this, the company expects to benefit from regional procurement, supply chain, and operational synergies through leveraging its existing capabilities in Japan and globally over a larger store network.

Domino’s Pizza Enterprises CEO & Managing Director, Don Meij, believes the Taiwanese market has significant potential.

He said: “This is a market with tremendous opportunity for our business and this acquisition provides similar opportunity for the local team. Our expansion focus has been on identifying opportunities with large total addressable markets and a stable economy – we look forward to bringing our High Volume Mentality to this business.”

“We have built centres of excellence in Australia/New Zealand, Europe and Asia, allowing us to complement local expertise in menu development and taste preferences with proven experience in technology, marketing, operations, and strategy and insights. Just as this approach has worked in Europe and more recently in Japan, we intend to apply the same lessons in the new market.”

“We intend to expand the store footprint through opening more corporate stores, introducing new, internal, franchisees to the network, helping existing franchisees profitably expand their businesses, and investing in the network and our people to drive long term growth.”

Earnings boost

The acquisition of Domino’s Taiwan is expected to give the company’s earnings a modest boost in the near term.

The acquired business delivered network sales of approximately A$73 million and earnings before interest, tax, depreciation and amortisation (EBITDA) of approximately A$4.8 million for FY 2020.

Based on this, the transaction is approximately 2% earnings per share accretive (excluding integration, reorganisation and transaction costs).

However, it may not stop at this acquisition. Management advised that it remains active in pursuing suitable additional markets as acquisition opportunities.

The Domino’s share price is up over 30% in 2021.

The post Domino’s (ASX:DMP) share price rises on a acquisition news appeared first on The Motley Fool Australia.

More reading

• Why Zip (ASX:Z1P) and this ASX growth share are highly rated by analysts
• Fund managers are buying Qantas (ASX:QAN) and this ASX share
• Which ASX retail shares are the latest trade winners?
• 2 outstanding ASX 200 growth shares
• ASX 200 down 0.15%: A2 Milk class action, Nuix crashes again

James Mickleboro does not own Domino’s shares. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Dominos Pizza Enterprises Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3zmENX8

The AMP Ltd (ASX: AMP) share price is edging lower on Friday morning despite announcing a key new appointment.

At the time of writing, the financial services company’s shares are down 0.5% to $1.20.

Despite this, the AMP share price is still up 10% since this time last month.

What did AMP announce?

This morning AMP announced the appointment of its new Chief Executive Officer (CEO) for the AMP Capital business.

According to the release, the company has named internationally respected asset management executive Shawn Johnson as the CEO of AMP Capital.

Mr Johnson previously served as Senior Managing Director and Chairman of the Investment Committee of State Street Global Advisors (SSGA) for almost a decade.

In this role, he had global oversight and responsibility for over 450 investment strategies and US$2.1 trillion in client assets. This includes the management of all SSGA’s private equity businesses.

In addition to this, while at SSGA, Mr Johnson also served as the volunteer Chairman of the Financial Services Sector Coordinating Council (FSSCC) from 2008 to 2010. FSSCC is a non-profit organisation that coordinates critical infrastructure and US homeland security activities within the financial services industry. It works collaboratively with key government agencies.

Furthermore, Mr Johnson has recently been leading his own alternative investments businesses, including management of a global macro hedge fund and various private investment strategies.

What now?

The release explains that as AMP Capital CEO, Mr Johnson will lead its international growth strategy and the proposed demerger of the private markets businesses. The latter is expected to complete in the first half of FY 2022.

He will commence in the role from 28 June and be based initially in Sydney. However, he will also work on a global basis across the key international offices of the Private Markets business.

AMP’s Chair, Debra Hazelton, commented: “We are delighted to announce the appointment of Shawn as AMP Capital Chief Executive. Shawn’s extensive experience and knowledge of global investment management, particularly private markets, makes him an exceptional leader for AMP Capital. His experience as a leader in one of the world’s largest asset management firms, State Street Global Advisors, where he played a key role in markedly growing the business and navigating the global financial crisis, will be invaluable.”

The incoming AMP Capital CEO revealed that he sees significant growth potential for the business and is excited for the challenge.

Mr Johnson commented: “AMP Capital is a globally-respected investment manager, and I’m excited by the significant potential for international growth but also in Australia. I’m confident of its underlying strength and the depth of its investment, distribution, and operational talent. Our focus will be to harness these strengths as we set up as a new, independent organisation following separation from AMP.”

“It’s an exciting challenge to which I believe I can bring my experience, passion and energy for growing businesses and leading a highly skilled organisation. I look forward to working alongside our talented teams, meeting our key clients, and moving our business forward.”

In other news, AMP confirmed that Alexis George will commence as group CEO on 2 August 2021.

The post AMP (ASX:AMP) share price lower despite key new appointment appeared first on The Motley Fool Australia.

More reading

• Here’s what I think of Coles, PointsBet, NAB, AMP: analyst
• Why AMP, Champion Iron, EOS, & Vulcan shares are storming higher
• Warning: We’ve hit the bottom of a 40-year cycle, says expert
• AMP (ASX:AMP) share price on watch after being hit with civil proceedings
• Why is the AMP (ASX:AMP) share price falling again today?

James Mickleboro does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3g8ZBts